OncoMatch/Clinical Trials/NCT03949231

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

Is NCT03949231 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies PD1/PDL1 inhibitor for liver cancer.

Phase 3RecruitingSecond Affiliated Hospital of Guangzhou Medical UniversityNCT03949231Data as of May 2026

Treatment: PD1/PDL1 inhibitor — This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: transplantation

Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on

Cannot have received: resection

Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on

Cannot have received: radiotherapy

Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on

Cannot have received: chemotherapy

Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on

Lab requirements

Blood counts

WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control

Kidney function

Cr ≤ 145.5 umul/L; Renal failure / insufficiency requiring hemo- or peritoneal dialysis [excluded]

Liver function

Child-Pugh class A or B/Child score > 7; Albumin > 28 g/L; Total bilirubin < 51 μmol/L

Child-Pugh class A or B/Child score > 7; WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]; Renal failure / insufficiency requiring hemo-or peritoneal dialysis [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify